Browsing Tag
TAVNEOS
3 posts
Why Amgen’s Tavneos trouble may be more than just another FDA safety review
Find out why Amgen’s Tavneos review could reshape rare disease drug regulation, investor sentiment, and biotech M&A risk.
CSL (ASX: CSL) crashes 17.7% to A$98.59 after FY26 guidance cut and $5bn impairments
CSL cut FY26 NPATA to US$3.1 billion and flagged US$5 billion in impairments. The third downgrade in ten months is repricing the entire ASX healthcare sector.
Amgen to acquire American biopharma company ChemoCentryx for $3.7bn
Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases…